New from NICE

In 2009, NICE recommended ustekinumab (Stelara), a monoclonal antibody against interleukins 12 and 23, as an option for the treatment of moderate to severe plaque psoriasis. In Technology Appraisal 313, it has now declined to recommend its use for active psoriatic arthritis.

New from NICE 19 Jun

Add yours ↓
Web design and marketing agency Leamington Spa